规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
靶点 |
Endogenous Metabolite
|
---|---|
体外研究 (In Vitro) |
当与LPS(1 μg/ml)、ATP二钠盐水合物(5 mM)联合使用1小时时,对激活HGF中的NLRP3炎症小体具有协同作用[3]。在体外,骨髓源性巨噬细胞 (BMDM) 响应 ATP 二钠盐水合物(2 mM;0.5-24 小时),以依赖于 caspase-1 激活的方式分泌白介素 1β、KC 和 MIP-2[4] 。体外中性粒细胞趋化性由ATP二钠盐水合物直接和间接诱导,同时刺激细胞因子和趋化因子的释放以及炎症小体的激活[4]。
|
体内研究 (In Vivo) |
腹腔注射 50 mg/kg ATP 二钠盐水合物的小鼠可免受细菌感染[4]。 ?体内中性粒细胞的募集和 KC、MIP-2 和 IL1β 的释放是由 ATP 二钠盐水合物诱导的[4]。
|
酶活实验 |
人类健康不断受到各种各样的危险的威胁,包括自身的和非自身的。免疫系统的任务是保护宿主免受这些危险,以保护人体健康。为此,免疫系统配备了各种各样的细胞和非细胞效应物,这些效应物彼此之间保持着持续的联系。自然产生的核苷酸腺苷5'-三磷酸(ATP)及其代谢物腺苷(Ado)可能通过嘌呤能信号通过其同源受体构成了这个广泛的免疫网络的固有组成部分,这些受体在全身广泛表达。本文综述了ATP和Ado对主要免疫细胞类型的影响。大量证据表明,ATP和Ado在免疫和炎症反应中是重要的内源性信号分子。尽管ATP和Ado在体内炎症和免疫反应过程中的作用似乎非常复杂,但我们认为它们的免疫作用是相互依赖的,是多方面的,这意味着它们的作用性质可能从免疫刺激转变为免疫调节,反之亦然,这取决于细胞外浓度以及嘌呤能受体和外泌酶的表达模式。嘌呤能信号因此有助于炎症和免疫反应的微调,以这样一种方式,对宿主的危险被有效地消除,对健康组织的损害最小。[2]
|
动物实验 |
Animal/Disease Models: Fourweeks old Kunming mice (18-22 g)[4]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip)injection, before bacterial (E. coli) challenge Experimental Results: Protected mice from bacterial infection. |
参考文献 | |
其他信息 |
Since 1929, when it was discovered that ATP is a substrate for muscle contraction, the knowledge about this purine nucleotide has been greatly expanded. Many aspects of cell metabolism revolve around ATP production and consumption. It is important to understand the concepts of glucose and oxygen consumption in aerobic and anaerobic life and to link bioenergetics with the vast amount of reactions occurring within cells. ATP is universally seen as the energy exchange factor that connects anabolism and catabolism but also fuels processes such as motile contraction, phosphorylations, and active transport. It is also a signalling molecule in the purinergic signalling mechanisms. In this review, we will discuss all the main mechanisms of ATP production linked to ADP phosphorylation as well the regulation of these mechanisms during stress conditions and in connection with calcium signalling events. Recent advances regarding ATP storage and its special significance for purinergic signalling will also be reviewed. [1]
It has been established that Adenosine-5'-triphosphate (ATP) can activate the NLRP3 inflammasome. However, the physiological effect of extracellular ATP on NLRP3 inflammasome activation has not yet been investigated. In the present study, we found that ATP was indeed released during bacterial infection. By using a murine peritonitis model, we also found that ATP promotes the fight against bacterial infection in mice. ATP induced the secretion of IL-1β and chemokines by murine bone marrow-derived macrophages in vitro. Furthermore, the intraperitoneal injection of ATP elevated the levels of IL-1β and chemokines in the mouse peritoneal lavage. Neutrophils were rapidly recruited to the peritoneum after ATP injection. In addition, the effects on cytokine and chemokine secretion and neutrophil recruitment were markedly attenuated by the pre-administration of the caspase-1 inhibitor Ac-YVAD-cho. Ac-YVAD-cho also significantly attenuated the protective effect of ATP against bacterial infection. In the present study, we demonstrated a protective role for ATP during bacterial infection and this effect was related to NLRP3 inflammasome activation. Together, these results suggest a role for ATP in initiating the immune response in hosts suffering from infections. [4] |
分子式 |
C10H16N5NA2O14P3
|
---|---|
分子量 |
569.160
|
精确质量 |
568.97
|
元素分析 |
C, 21.10; H, 2.83; N, 12.30; Na, 8.08; O, 39.35; P, 16.33
|
CAS号 |
34369-07-8
|
相关CAS号 |
ATP disodium salt;987-65-5;ATP disodium trihydrate;51963-61-2;ATP dimagnesium;74804-12-9;ATP-13C10,15N5 disodium;ATP disodium salt hydrate;34369-07-8;ATP dipotassium;42373-41-1;ATP ditromethamine;102047-34-7;ATP-13C10,15N5;752972-20-6
|
PubChem CID |
16218877
|
外观&性状 |
White to off-white solid powder
|
tPSA |
286Ų
|
SMILES |
O[C@@H]([C@H]([C@H](N1C=NC2=C(N=CN=C21)N)O3)O)[C@H]3COP([O-])(OP(O)(OP([O-])(O)=O)=O)=O.[H]O[H].[Na+].[Na+]
|
InChi Key |
NTBQNWBHIXNPRU-MSQVLRTGSA-L
|
InChi Code |
InChI=1S/C10H16N5O13P3.2Na.H2O/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20;;;/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20);;;1H2/q;2*+1;/p-2/t4-,6-,7-,10-;;;/m1.../s1
|
化学名 |
O[C@@H]([C@H]([C@H](N1C=NC2=C(N=CN=C21)N)O3)O)[C@H]3COP([O-])(OP(O)(OP([O-])(O)=O)=O)=O.[H]O[H].[Na+].[Na+]
|
别名 |
34369-07-8; ATP disodium salt; ATP disodium salt hydrate; Adenosine 5'-triphosphate disodium salt hydrate; MFCD00150755; Adenosine 5'-triphosphate disodium salt hydrate; disodium;[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;hydrate; ATP (disodium salt hydrate);
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意: 请将本产品存放在密封且受保护的环境中,避免吸湿/受潮。 |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
H2O : ~100 mg/mL
|
---|---|
溶解度 (体内实验) |
配方 1 中的溶解度: 100 mg/mL (Infinity mM) in PBS (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液; 超声助溶。
请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7570 mL | 8.7849 mL | 17.5698 mL | |
5 mM | 0.3514 mL | 1.7570 mL | 3.5140 mL | |
10 mM | 0.1757 mL | 0.8785 mL | 1.7570 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。